ADPT Earnings

ADPT reported its earnings on 2026-05-05, showcasing a revenue of 70.87M against an estimate of 61.84M, resulting in a 14.61% surprise. The EPS was -0.13, surpassing the expected -0.16 by 18.75%. The stock experienced a 4.72% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following ADPT's earnings announcement on 2026-05-05, the stock price moved by 4.72% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, ADPT's stock price tends to shift by an average of -1.51% in the 10 days leading up to earnings and 4.97% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate ADPT's annual revenue to reach 65.85M, while the EPS is projected at -0.14. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ADPT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ADPT's stock price typically moves by -1.51% in the 10 days before its earnings and 4.97% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of -0.14 and revenue of 65.85M.

The earnings call reflects strong revenue growth driven by MRD, improved EBITDA in the MRD segment, and optimistic guidance with margin expansion and increased pharma partnerships. Despite some concerns about expenses and ongoing investments, the market strategy and business updates are robust. The Q&A highlights progress in community account engagement, reimbursement profiles, and EHR integration, with positive analyst sentiment. While some uncertainties remain, particularly around Medicare bundle increases and contract transitions, the overall sentiment is positive, anticipating a 2-8% stock price increase.